NVCTHealthcareSmall-Cap

Nuvectis Pharma, Inc. Insider Trading Activity

Every SEC Form 4 insider transaction reported for Nuvectis Pharma, Inc. (NVCT), sourced directly from SEC EDGAR and updated as new filings are accepted.

Last updated:

Quick Answer

Are NVCT insiders buying or selling?

Nuvectis Pharma, Inc. insiders reported 92 open-market buys ($10.9M) and 1 sells ($22.5K) across 93 Form 4 filings — a net buying position of $10.8M.

Source: SEC EDGAR Form 4

Key Statistics (as of Jul 1, 2026)

Total Form 4 filings
93
SEC EDGAR
Insider filers
8
Insider buys (92)
$10.9M
Insider sells (1)
$22.5K

Insider sentiment

Net buying

Net insider flow of $10.8M in net buying. 2 insider buys in the last 90 days.

Recent NVCT insider transactions

DateInsiderRoleTypeSharesPriceValue
Jul 1, 2026Mosseri Marlio Charles10% OwnerPurchase50.0K$18.32$916.0K
Jul 1, 2026Ron BentsurChairman & CEOPurchase12.5K$20.00$250.0K
Nov 6, 2025Ron BentsurChairman & CEOPurchase5.0K$5.72$28.6K
Nov 6, 2025Juan SanchezDirectorPurchase13.0K$5.79$75.3K
Nov 6, 2025Matthew L. KaplanDirectorPurchase11.0K$5.84$64.2K
Oct 29, 2025Mosseri Marlio Charles10% OwnerPurchase154.8K$6.18$957.1K
Jun 24, 2025Mosseri Marlio Charles10% OwnerPurchase5.6K$7.99$44.8K
Jun 20, 2025Mosseri Marlio Charles10% OwnerPurchase33.4K$8.06$269.5K
May 13, 2025Mosseri Marlio Charles10% OwnerPurchase21.2K$8.11$171.7K
May 12, 2025Mosseri Marlio Charles10% OwnerPurchase27.7K$8.94$247.3K
May 9, 2025Mosseri Marlio Charles10% OwnerPurchase27.4K$8.60$235.6K
Feb 11, 2025Mosseri Marlio Charles10% OwnerPurchase240.0K$5.00$1.2M
Dec 26, 2024Ron BentsurChairman & CEOPurchase4.5K$4.65$20.9K
Dec 16, 2024Mosseri Marlio Charles10% OwnerPurchase49.1K$4.66$228.9K
Dec 16, 2024Mosseri Marlio Charles10% OwnerPurchase17.0K$4.70$79.9K
Nov 20, 2024Poradosu EnriqueChief Science & Business OffPurchase2.0K$4.99$10.0K
Nov 18, 2024Ron BentsurChairman & CEOPurchase20.0K$4.92$98.4K
Nov 8, 2024Michael J. CarsonVice President, FinanceSale2.8K$8.16$22.5K
May 15, 2024Ron BentsurChairman & CEOPurchase1.9K$6.74$13.1K
May 13, 2024Ron BentsurChairman & CEOPurchase2.0K$6.40$12.8K
May 13, 2024Poradosu EnriqueChief Science & Business OffPurchase500$6.29$3.1K
May 13, 2024Shemesh ShayChief Dev. & Ops. OfficerPurchase1.1K$6.32$7.0K
Oct 12, 2023Ron BentsurChairman & CEOPurchase640$11.08$7.1K
Oct 10, 2023Ron BentsurChairman & CEOPurchase1.1K$11.21$12.1K
Oct 6, 2023Ron BentsurChairman & CEOPurchase3.2K$11.01$35.5K

Showing the 25 most recent of 93 Form 4 filings for Nuvectis Pharma, Inc..

Most active NVCT insiders

  • Ron Bentsur45 filings
  • Mosseri Marlio Charles26 filings
  • Shemesh Shay12 filings
  • Poradosu Enrique5 filings
  • Matthew L. Kaplan2 filings

Ask anything about NVCT insider activity

Use Trabud's AI agent to query Nuvectis Pharma, Inc.'s Form 4 history in plain English — "Show me NVCT CEO purchases this year" or compare it against any other ticker.

Open the AI agent

NVCT insider trading FAQ

Are Nuvectis Pharma, Inc. insiders buying or selling?

Across 93 SEC Form 4 filings, Nuvectis Pharma, Inc. (NVCT) insiders reported 92 open-market purchases totaling $10.9M and 1 sales totaling $22.5K. That is a net buying position of $10.8M.

How many insiders trade NVCT stock?

8 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Nuvectis Pharma, Inc.. The most recent filing was accepted on Jul 1, 2026.

Where does Trabud get NVCT insider trading data?

All NVCT insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.

Looking for another company? Browse all tracked companies.

Related Content